Payment overview · 2025
General Payments
$299.95
2 reported records · 2 companies
Healthcare provider profile · identity verified
Farzin Sehati, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FOREST HILLS, NY · NPI 1477636389
Verified facts
What the public records show
CMS Open Payments records show Farzin Sehati, D.O. received $299.95 in general payments during 2025 across 2 reported records.
Intra-Sana Laboratories accounted for 50.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $150.00 | 50.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $149.95 | 50.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $299.95 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $149.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 363 | 79 |
| Furosemide | Furosemide | 333 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 313 | 58 |
| Eliquis | Apixaban | 302 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 241 | 52 |
| Donepezil Hcl | Donepezil Hcl | 219 | 38 |
| Trazodone Hcl | Trazodone Hcl | 180 | 36 |
| Memantine Hcl | Memantine Hcl | 179 | 27 |
| Losartan Potassium | Losartan Potassium | 176 | 37 |
| Gabapentin | Gabapentin | 160 | 28 |
| Mirtazapine | Mirtazapine | 150 | 35 |
| Sertraline Hcl | Sertraline Hcl | 145 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 133 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | 26 |
| Potassium Chloride | Potassium Chloride | 117 | 20 |
| Famotidine | Famotidine | 107 | 26 |
| Lisinopril | Lisinopril | 104 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 89 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 23 |
| Carvedilol | Carvedilol | 82 | 16 |
| Finasteride | Finasteride | 82 | 12 |
| Omeprazole | Omeprazole | 74 | 18 |
| Simvastatin | Simvastatin | 74 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 12 |
| Valsartan | Valsartan | 67 | 11 |
| Metformin Hcl | Metformin Hcl | 63 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 14 |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 13 |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Latanoprost | Latanoprost | 50 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 39 |
| Risperidone | Risperidone | 48 | 14 |
| Tramadol Hcl | Tramadol Hcl | 48 | 19 |
| Xarelto | Rivaroxaban | 43 | 11 |
| Azithromycin | Azithromycin | 42 | 36 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 42 | 28 |
| Methenamine Hippurate | Methenamine Hippurate | 42 | 13 |
| Enalapril Maleate | Enalapril Maleate | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 37 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Alprazolam | Alprazolam | 34 | 11 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Pregabalin | Pregabalin | 34 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Prednisone | Prednisone | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Meloxicam | Meloxicam | 27 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | suppressed |
| Glimepiride | Glimepiride | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Droxidopa | Droxidopa | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 15 |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 18 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 18 | suppressed |
| Tobramycin | Tobramycin | 18 | 16 |
| Allopurinol | Allopurinol | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Silodosin | Silodosin | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Matzim La | Diltiazem Hcl | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $299.95 · 2 records | Intra-Sana Laboratories | FREESTYLE LIBRE 3, GLYCATE, RELTONE 200 MG, RELTONE 400 MG | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error